NSE filing, NSE: EMMBI. Summary written from the filing by ALFA Finder's alert engine.
Emmbi Industries Ltd: key numbers
- Share price
- ₹74.99
- Market cap
- ₹144.3 Cr
- Revenue (annual)
- ₹455.5 Cr
- Net profit (annual)
- ₹7.89 Cr
- P/E (TTM)
- 17.3×Sector 45.0×
- Promoter holding
- 62.95%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Emmbi Industries Ltd
All →Emmbi Industries Acquisition Worth ₹0.01 Cr
Emmbi's subsidiary Zastian will buy 50% of Sweden's Britpac AB for about Rs 0.01 Crore. Britpac has not started trading; the deal targets international expansion.
- Value
- ₹0.01 Cr
Emmbi Industries Q2 FY27 Results: Net Profit ₹2.5 Cr, Down 13.8% YoY
Emmbi Industries Ltd reported revenue from operations of ₹136.7 Cr (+12.0% YoY) and net profit of ₹2.5 Cr (-13.8% YoY) for Q2 FY27.
- Key figure
- Net profit ₹2.5 Cr · -13.8% YoY
Emmbi Industries Board Meeting Date
Emmbi Industries Limited has scheduled a board meeting on October 29, 2026, to consider and approve the financial results for the quarter and half-year ended September 30, 2026.
Emmbi Industries Board Meeting Outcome
Emmbi Industries Limited announced the reconstitution of its Board committees, including the Audit, Nomination, Stakeholder, and CSR committees. This update concerns routine board administrative governance.
Emmbi Industries Other Announcement
Emmbi Industries Limited submitted the quarterly certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the period ended September 30, 2026.
Emmbi Industries Management Change
Emmbi Industries appointed three directors at its 32nd AGM: Anuj Choksey (Independent) and two Executive Directors. The moves strengthen board governance and add capital markets expertise.
Other regulatory approval announcements
All →Bliss GVS Pharma Regulatory Approval
Bliss GVS Pharma's UK subsidiary Asterisk Lifesciences received MHRA marketing authorisation for Mesalazine 1g Suppositories. The approval lets the subsidiary market the product in the UK.
John Cockerill India Regulatory Approval
John Cockerill India received Reserve Bank of India approval for acquiring shares of John Cockerill Metals International SA. This allows the company to proceed with the share-swap acquisition.
Gland Pharma Regulatory Approval
Gland Pharma received USFDA approval for Methylprednisolone Acetate Injectable Suspension USP in multiple vial formats. The product is bioequivalent to Pfizer's Depo-Medrol in a ~$214M US market.
City Union Bank Regulatory Approval
City Union Bank disclosed RBI approval for appointing Shri Sankaran G as Executive Director (Whole-time Director) for three years. The board appointment and formal disclosures will follow later.
- Execution
- Three years from the date of taking charge
Lupin Regulatory Approval
Lupin received US FDA approval for its generic Amifampridine Tablets 10 mg ANDA. As a first-to-file applicant, it is eligible for 180-day shared generic exclusivity.
Som Distilleries & Breweries Regulatory Approval
Som Distilleries received manufacturing licences for its Bhopal plant from the Madhya Pradesh Excise Department, plus product label and rate approvals. Manufacturing and sales are expected to resume soon.